Detalhe da pesquisa
1.
The mutational landscape of mucosal melanoma.
Semin Cancer Biol
; 61: 139-148, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31655118
2.
AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition.
Med Oncol
; 40(10): 299, 2023 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37713162
3.
Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma.
Mol Cancer Ther
; 20(10): 2049-2060, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34376578
4.
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells.
Cell Death Dis
; 11(6): 443, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32513939
5.
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy.
Cancers (Basel)
; 12(7)2020 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32708981
6.
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Oncogenesis
; 7(2): 23, 2018 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-29487290